Rundu Pharmaceuticals Plans to Expand Nicotine Products Overseas

Jan.23.2025
Rundu Pharmaceuticals Plans to Expand Nicotine Products Overseas
Investors inquire about potential collaboration with Swedish match company and US nicotine pouch sales for Ruando Group (002923.SZ).

Recently, an investor raised questions on the interactive platform asking whether Runto Corporation (002923.SZ) is collaborating with Swedish Match AB and whether they have plans to register their brand to sell nicotine pouch products in the United States.


In response to this, Runto Pharmaceuticals stated that the quality of the bioalkaloids (nicotine) produced by its wholly-owned subsidiary Runto Pharmaceuticals (Jingmen) Co., Ltd. has been widely recognized and has achieved commercial sales. Nicotine products can be applied in various fields such as pharmaceuticals, pesticides, e-cigarettes, nicotine pouches, and nicotine patches, with a wide range of applications. The company will actively understand the relevant domestic and foreign market access rules, strive to gain more commercial cooperation opportunities, and provide better returns for investors.


We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

BAT faces London shareholder lawsuit over alleged disclosure failures tied to North Korea business
BAT faces London shareholder lawsuit over alleged disclosure failures tied to North Korea business
British American Tobacco is facing a shareholder lawsuit in London alleging it failed to properly disclose to markets information about breaches of U.S. sanctions linked to its North Korea-related business. BAT agreed in 2023 to pay more than $635 million to U.S. authorities after a subsidiary admitted conspiring to violate U.S. sanctions by selling tobacco products to North Korea and committing bank fraud from 2007 to 2017.
Mar.05 by 2FIRSTS.ai
South Korea’s appeal court again sides with KT&G, Philip Morris Korea and BAT Korea in $36.24 million case
South Korea’s appeal court again sides with KT&G, Philip Morris Korea and BAT Korea in $36.24 million case
South Korea’s National Health Insurance Service (NHIS) has again lost on appeal in its damages lawsuit against KT&G, Philip Morris Korea and BAT Korea, seeking ₩53.3 billion (about $36.244 million).
Jan.15 by 2FIRSTS.ai
2Firsts Interview with Glas |Why a California ENDS Company Believes Its Age-gated Flavored Vape Could Be Next in Line for FDA Authorization
2Firsts Interview with Glas |Why a California ENDS Company Believes Its Age-gated Flavored Vape Could Be Next in Line for FDA Authorization
As the FDA advances efforts to streamline its PMTA review process, including support for small businesses, expectations are rising that additional product authorizations may follow. Age-verification technology is emerging as a key consideration in future approvals.In this interview, California-based Glas discusses its G2 platform, integrating smartphone-based identity verification, proximity controls and anti-counterfeit systems, and outlines its positioning under the FDA’s PMTA framework.
Mar.02
Product | 5ml/2ml Dual Versions, Up to 45W Output: VAPORESSO Launches LUXE X3 on Official Website
Product | 5ml/2ml Dual Versions, Up to 45W Output: VAPORESSO Launches LUXE X3 on Official Website
VAPORESSO has listed the LUXE X3, a new addition to its LUXE X series, on its official website. The device features a 2,600mAh built-in battery, adjustable 5–45W output and a 0.8-inch digital display, and comes with a 5ml pod (2ml for the TPD version). The LUXE X3 has also appeared on some UK and US online retailers for pre-order, with prices below the company’s stated MSRP of $37.9.
Jan.19 by 2FIRSTS.ai
Special Report | Breeze and Glas Seek White House Review as FDA Advances Flavored ENDS Guidance
Special Report | Breeze and Glas Seek White House Review as FDA Advances Flavored ENDS Guidance
Breeze Smoke and Glas, Inc. have separately requested White House review under Executive Order 12866 as the FDA advances draft guidance on flavored ENDS (RIN 0910-ZC78). The guidance aims to clarify evidentiary standards under the statutory “appropriate for the protection of public health” (APPH) framework. The parallel filings highlight industry concern over regulatory predictability, particularly as Glas’s PMTA review status has recently drawn market attention.
Special Report
Mar.03
Product | Claiming a “first multi-beverage vaporizer” with refillable juice/cocktail water chamber, PEAKBAR launches new device in the U.S.
Product | Claiming a “first multi-beverage vaporizer” with refillable juice/cocktail water chamber, PEAKBAR launches new device in the U.S.
PEAKBAR’s new H2O 40K has begun selling through U.S. online retailers including Vape Sourcing. Marketed as the “world’s first multi-beverage vaporizer,” the device is promoted as allowing users to add liquids such as juice and cocktails into a water chamber for pairing. Publicly listed specifications include 20 ml of e-liquid, a rated 40,000 puffs, 0.5% nicotine, a 1,000 mAh rechargeable battery, and two power modes at 22W and 12W.
Jan.22 by 2FIRSTS.ai